1.1.1 Cell and gene therapies, collectively referred to as advanced therapies, gain much media attention due to their promise for curative treatments, especially for devastating rare genetic diseases, and their extraordinarily high prices. Within the industry, they are also known for their high cost of goods, and difficulties in development and manufacturing as well as their astounding promise for patients and investors.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
1.2.1 The idea that a “good” piece of DNA could replace a “defective” section causing genetic disease was first proposed by Friedmann and Roblin in 1972 in a seminal paper in Science.[6] This idea became the central tenet of gene therapy.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
1.3.1 In addition to viral vectors derived from viruses that infect animals and insects, plant-based viral vectors have emerged as valuable tools for a range of applications in biotechnology, medicine, agriculture, and beyond. While traditionally used for genome editing and protein expression in plants, plant-based virus-like particles (VLPs) and virus nanoparticles (VNPs) are increasingly being investigated for non-drug-related therapeutic, diagnostic, and environmental applications.[12]
1.3.2 Three of the most common plant-based viruses used in this space include tobacco mosaic virus (TMV), potato virus X (PVX), and cowpea mosaic virus (CPMV). These viruses, along with others like geminiviruses, have been repurposed as vehicles for delivering therapeutic genes, imaging agents, and small molecules.[13] They offer a versatile platform due to their nonpathogenic nature in humans, ease of production, and biocompatibility. Their rapid manufacturability and modifiability, including conjugation and genetic engineering, allow for innovative applications across several fields.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
1.4.1 In early 2024, we received many questions regarding the funding outlook for biotech. The following is our answer to these questions. While the text was also published on Pharma’s Almanac under the name “Biotech Funding Ups and Downs” in April 2024,[19] we are reproducing it here for the convenience of our readers. The following sections update the history lesson for the 2024 outlook.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
1.5.1 So where do we stand, and what is the outlook for 2024? Analysts consider the bottleneck to be pharma acquisitions, so this is where we must look for forecasting the return of capital to the biotech markets. Although a few large exits, notably in the ADC space, have made news,[32][33][34] exit activity as of Q2 2024 is still depressed. PitchBook reported $14.5B in exits over 39 deals. When compared to the 2023 total ($20B over 97 deals), this indicates that the value of ongoing deals is at least on the rise, even if the total number of exits is not.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
1.6.1 The pharmaceutical industry, once buoyed by the unprecedented demand and rapid innovation triggered by the COVID-19 pandemic, is currently readjusting to a post-COVID world, which has brought its own challenges, including a wave of layoffs that has swept across the biotech and pharma landscape in the past few years. This undercurrent of job reductions and corporate restructuring echoes the industry’s reflex to recalibrate in response to market pressures and strategic realignments, which appears at odds with forecasts of robust drug sales and potential market growth.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.